Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease multiple myeloma
Comorbidity C0005940|bone disease
Sentences 33
PubMedID- 21403648 myeloma patients with extensive bone disease have high serum levels of ccl3 (21).
PubMedID- 24164102 Zoledronic acid (zol) is frequently used for the treatment of bone disease in patients with multiple myeloma and breast cancer with metastasis to bone.
PubMedID- 25626302 Osteolytic bone disease in multiple myeloma (mm) affects more than 80% of patients.
PubMedID- 21569702 Objective: to explore the difference of effects of two regimens (bortezomib and dexamethasone, bd; and thalidomide and dexamethasone, td) on bone disease in multiple myeloma (mm).
PubMedID- 22726547 bone disease in patients with multiple myeloma (mm) is characterized by increase in the numbers and activity of bone-resorpting osteoclasts and decrease in the number and function of bone-formation osteoblasts.
PubMedID- 22902442 [management of bone disease in multiple myeloma].
PubMedID- 22498739 Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the medical research council myeloma ix trial.
PubMedID- 21745013 bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.
PubMedID- 21732484 multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses.
PubMedID- 23431957 Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
PubMedID- 22952578 Furthermore, studies aimed at clarifying the importance of osteoporosis in the bone disease associated with multiple myeloma, as well as the mechanism(s) involved, will help provide the rationale for targeting this component of the disease.
PubMedID- 20572008 Our group has examined their role in the progression of the osteolytic bone disease associated with multiple myeloma.
PubMedID- 20863761 Interpretation: monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
PubMedID- 23416846 No anabolic drugs are currently approved to treat multiple myeloma (mm)-induced bone disease and the anti-mm agent bortezomib exhibits the anabolic effects in the clinic.
PubMedID- 24249482 The effects of bortezomib on bone disease in patients with multiple myeloma.
PubMedID- 22454220 Zoledronic acid (zol), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal-related events (sres) in multiple myeloma (mm) patients with bone disease.
PubMedID- 20722619 For over 2 decades bisphosphonates have been successfully used to treat the tumour-induced bone disease associated with multiple myeloma.
PubMedID- 23417027 Given the prevalence of osteolytic bone disease in multiple myeloma (mm), novel therapies targeting bone microenvironment are essential.
PubMedID- 25187738 bone disease in multiple myeloma: pathophysiology and management.
PubMedID- 26345558 [management of bone disease in myeloma patients: zoledronic acid or denosumab.
PubMedID- 24422114 Thus, bortezomib is recommended for myeloma patients with extended bone disease in combination with bisphosphonates.
PubMedID- 24381787 Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.
PubMedID- 25628928 Osteolytic bone disease in multiple myeloma (mm) is associated with upregulated osteoclast activity.
PubMedID- 21991938 Osteolytic bone disease is a hallmark of symptomatic multiple myeloma.
PubMedID- 24074513 Objectives: bone disease is one of the hallmarks of multiple myeloma (mm).
PubMedID- 20664052 Osteoclast (oc)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma.
PubMedID- 21411443 Osteolytic bone disease is pathognomonic of multiple myeloma (mm) and affects more than 80% of patients.
PubMedID- 24433088 Management of bone disease in multiple myeloma.
PubMedID- 24656650 Bone marrow plasma macrophage inflammatory protein protein-1 alpha(mip-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.
PubMedID- 23931337 Serum c terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
PubMedID- 21649546 Traditionally, the skeletal survey has been the standard modality for the detection of osteolytic bone disease in multiple myeloma.
PubMedID- 25744289 Purpose: multiple myeloma (mm) is often associated with osteolytic bone disease and anemia, resulting in skeletal fragility and persistent fatigue, pain, and reduced quality of life.
PubMedID- 25491781 Diagnosis of mm is made based on the clonal plasmacytosis of at least 15% on bone marrow examination or biopsy-proven clonal plasmacytoma, the presence of m protein in serum or urine, and any evidence of end-organ damage (i.e., hypercalcemia, renal insufficiency, anemia, and bone disease) attributable to myeloma involvement [7].

Page: 1